Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 26 Issue 8, August 2008

An artist's impression of targeted delivery of cytotoxic drugs to a cancer cell by internalization of the complex formed between antibody-drug conjugate (AD C) and its antigen. Junutula et al. produce near-homogenous AD Cs that are better tolerated than conventional AD Cs without any loss of anti-tumor activity (p 925). Credit: Allison Bruce, Genentech, Inc.

Volume 26 Issue 8

Subscribe

Editorial

  • Pushing biotech as the 'solution' to the world's problems is doing more harm than good.

    Editorial

    Advertisement

Top of page ⤴

News

Top of page ⤴

Data Page

Top of page ⤴

News Feature

  • Receiving only a fraction of the investment set aside for biofuels, biomaterials will likely have to piggyback on technological advances in energy production to compete with petroleum-based products in the marketplace. Emily Waltz reports.

    • Emily Waltz
    News Feature
Top of page ⤴

Correspondence

Top of page ⤴

Feature

  • Off-label prescribing is a fundamental fact of life of healthcare systems, but the promotion of off-label uses by drug sponsors is a fundamental sin. Regulators, legislators and drug makers are wrestling to find the right balance.

    • Mark Ratner
    • Trisha Gura
    Feature
Top of page ⤴

Patents

Top of page ⤴

News & Views

Top of page ⤴

Commentary

Top of page ⤴

Primer

Top of page ⤴

Perspective

Top of page ⤴

Article

  • Biological control of the root-knot nematode Meloidogyne incognita, one of the world's most destructive crop pathogens, presents a major opportunity for safely improving global agricultural yields. Its 86-Mb genome—the first to be sequenced for a strictly parthenogenetic species—provides a blueprint to design new strategies for plant protection.

    • Pierre Abad
    • Jérôme Gouzy
    • Patrick Wincker
    Article Open Access

  • Generating induced pluripotent stem (iPS) cells is still an inefficient process, in part because the delivery of reprogramming factors by retroviral vectors yields cell populations that are genetically heterogeneous. Wernig et al. increase efficiency by producing iPS-cell chimeric mice from which they isolate cells bearing identical proviral insertions that support drug-inducible reprogramming.

    • Marius Wernig
    • Christopher J Lengner
    • Rudolf Jaenisch
    Article

  • Systemic toxicity associated with heterogeneity in the stoichiometries and sites of drug attachment is a major hurdle to developing antibody-drug conjugates (ADCs) for cancer therapy. Junutula et al. engineer cysteine residues in constant domains to produce near-homogenous ADCs that are better tolerated than conventional ADCs, without any loss of antitumor activity.

    • Jagath R Junutula
    • Helga Raab
    • William Mallet
    Article

  • Little is known about the regulation of RNA interference (RNAi). Shan et al. constructed a reporter system to monitor RNAi activity and identified a small molecule that increases RNAi by facilitating the interaction between small RNAs and a protein involved in small RNA loading and processing.

    • Ge Shan
    • Yujing Li
    • Peng Jin
    Article
Top of page ⤴

Letter

  • The targets of a microRNA (miRNA) are usually identified by computational analysis of sequences complementary to the miRNA. Working with inflorescence tissue of Arabidopsis, German et al. devise an experimental approach in which the products of miRNA-mediated cleavage are sequenced and used to identify miRNA–target RNA pairs.

    • Marcelo A German
    • Manoj Pillay
    • Pamela J Green
    Letter
Top of page ⤴

Erratum

Top of page ⤴

Careers and Recruitment

  • Scientists in newer member countries are learning how to use what the European Union offers.

    • Quirin Schiermeier
    Careers and Recruitment
Top of page ⤴

People

Top of page ⤴

Search

Advanced search

Quick links